Rong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rong Li has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Henry W. Long
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
69 shared publications - Xintao Qiu
Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, United States of America
67 shared publications - Toni K. Choueiri
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
35 shared publications - Matthew G. Oser
Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School
34 shared publications - Aaron N. Hata
Massachusetts General Hospital 7 Charlestown, MA
33 shared publications - Jacob E. Berchuck
Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, GA 30322
33 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Springer Nature in Research Square
Functional epigenomic liquid biopsy identifies potential therapeutic vulnerabilities after enfortumab vedotin–pembrolizumab resistance in metastatic urothelial carcinoma (mUC)
Enfortumab vedotin plus pembrolizumab (EV/P) is the standard first-line treatment for advanced urothelial carcinoma (UC), yielding unprecedented clinical benefit; however, resistance ultimately develops in many patients, and longitudinal liquid biopsy offers an opportunity to monitor tumor evolution and emerging therapeutic vulnerabilities. We collected 96 serial plasma samples from 48 patients with advanced UC treated with first-line EV/P, of which 79 samples from 41 patients passed predefined quality-control criteria for H3K4me2 cfChIP-seq profiling. Progression during EV/P was accompanied by regulatory reprogramming characterized by recurrent increases in ERBB3-associated H3K4me2 activity together with DNA damage response, replication stress, hypoxia and metabolic adaptation programs. Longitudinal patient-level analyses identified heterogeneous increases in potentially therapeutically relevant loci, including ERBB2, FGFR3, TACSTD2, WEE1, CD276 and PPARG, that were not evident at baseline in selected patients. Among three platinum-treated patients with longitudinal samples, the two patients deriving clinical benefit showed declining ERCC2, ERBB3 and BRCA2 regulatory activity, whereas the patient with progressive disease showed increased ERCC2 and ERBB3 activity. In one illustrative patient, increased ERBB2 regulatory activity at EV/P progression preceded a durable response to trastuzumab deruxtecan. These findings support prospective evaluation of longitudinal functional epigenomic profiling as a complementary approach for characterizing resistance and informing biomarker-guided treatment sequencing after EV/P.
- 19 October 2026
- Published by Springer Nature in Research Square
Open AccessFunctional epigenomic liquid biopsy identifies potential therapeutic vulnerabilities after enfortumab vedotin–pembrolizumab resistance in metastatic urothelial carcinoma (mUC)
Enfortumab vedotin plus pembrolizumab (EV/P) is the standard first-line treatment for advanced urothelial carcinoma (UC), yielding unprecedented clinical benefit; however, resistance ultimately develops in many patients, and longitudinal liquid biopsy offers an opportunity to monitor tumor evolution and emerging therapeutic vulnerabilities. We collected 96 serial plasma samples from 48 patients with advanced UC treated with first-line EV/P, of which 79 samples from 41 patients passed predefined quality-control criteria for H3K4me2 cfChIP-seq profiling. Progression during EV/P was accompanied by regulatory reprogramming characterized by recurrent increases in ERBB3-associated H3K4me2 activity together with DNA damage response, replication stress, hypoxia and metabolic adaptation programs. Longitudinal patient-level analyses identified heterogeneous increases in potentially therapeutically relevant loci, including ERBB2, FGFR3, TACSTD2, WEE1, CD276 and PPARG, that were not evident at baseline in selected patients. Among three platinum-treated patients with longitudinal samples, the two patients deriving clinical benefit showed declining ERCC2, ERBB3 and BRCA2 regulatory activity, whereas the patient with progressive disease showed increased ERCC2 and ERBB3 activity. In one illustrative patient, increased ERBB2 regulatory activity at EV/P progression preceded a durable response to trastuzumab deruxtecan. These findings support prospective evaluation of longitudinal functional epigenomic profiling as a complementary approach for characterizing resistance and informing biomarker-guided treatment sequencing after EV/P.
- Open Access
- 22 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Histone H4 lysine 20 tri-methylation safeguards breast cancer lineage fidelity and unfolded protein response
Triple-negative breast cancer (TNBC) has poor outcomes and few effective treatments, partly because of epigenetic heterogeneity. We show that the heterochromatin mark H4K20me3 is more variable than H3K9me3 across normal and malignant breast tissues, and that H4K20me3-enriched regions are linked to more open chromatin and active transcription. Pharmacologic inhibition of the H4K20me3 methyltransferases KMT5B and KMT5C with A-196 decreases H4K20me3 and increases H4K20me1 at loci involved in lineage identity, stress responses, and the cell cycle. A-196 suppresses tumor growth in vivo while promoting mesenchymal features and the unfolded protein response (UPR). Multi-omic profiling shows that mesenchymal TNBCs have the lowest H4K20me3 levels and the greatest sensitivity to UPR stress. In basal TNBC, KMT5B&5 C inhibition drives mesenchymal transition and elevated endoplasmic reticulum stress-associated growth arrest via E2F4. Combining A-196 with the HSP90, IRAK4 inhibitors, or STING agonist synergistically reduces TNBC tumor growth. These findings nominate KMT5B&5C as promising therapeutic targets in TNBC.
- 22 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessHistone H4 lysine 20 tri-methylation safeguards breast cancer lineage fidelity and unfolded protein response
Triple-negative breast cancer (TNBC) has poor outcomes and few effective treatments, partly because of epigenetic heterogeneity. We show that the heterochromatin mark H4K20me3 is more variable than H3K9me3 across normal and malignant breast tissues, and that H4K20me3-enriched regions are linked to more open chromatin and active transcription. Pharmacologic inhibition of the H4K20me3 methyltransferases KMT5B and KMT5C with A-196 decreases H4K20me3 and increases H4K20me1 at loci involved in lineage identity, stress responses, and the cell cycle. A-196 suppresses tumor growth in vivo while promoting mesenchymal features and the unfolded protein response (UPR). Multi-omic profiling shows that mesenchymal TNBCs have the lowest H4K20me3 levels and the greatest sensitivity to UPR stress. In basal TNBC, KMT5B&5 C inhibition drives mesenchymal transition and elevated endoplasmic reticulum stress-associated growth arrest via E2F4. Combining A-196 with the HSP90, IRAK4 inhibitors, or STING agonist synergistically reduces TNBC tumor growth. These findings nominate KMT5B&5C as promising therapeutic targets in TNBC.
- Open Access
- 24 November 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 24 (2)
scATAnno: Automated Cell Type Annotation for Single-cell ATAC Sequencing Data
Recent advances in single-cell epigenomic techniques have created a growing demand for scATAC-seq analysis. One key analysis task is to determine cell type identity based on the epigenetic data. We introduce scATAnno, a python package designed to automatically annotate scATAC-seq data using large-scale scATAC-seq reference atlases. This workflow generates the reference atlases from publicly available datasets enabling accurate cell type annotation by integrating query data with reference atlases, without the use of scRNA-seq data. To enhance annotation accuracy, we have incorporated KNN-based and weighted distance-based uncertainty scores to effectively detect cell populations within the query data that are distinct from all cell types in the reference data. We compare and benchmark scATAnno against 5 other published approaches for cell annotation, demonstrating superior performance in multiple data sets and metrics. We showcase the utility of scATAnno across multiple datasets, including peripheral blood mononuclear cell (PBMC), triple negative breast cancer (TNBC), and basal cell carcinoma (BCC), and demonstrate that scATAnno accurately annotates cell types across conditions. Overall, scATAnno is a useful tool for scATAC-seq reference building and cell type annotation in scATAC-seq data and can aid in the interpretation of new scATAC-seq datasets in complex biological systems. scATAnno is available online at https://scatanno-main.readthedocs.io/.
- 24 November 2025
- Published by Oxford University Press (OUP) in Genomics, Proteomics & Bioinformatics
- Vol. 24 (2)
Open AccessscATAnno: Automated Cell Type Annotation for Single-cell ATAC Sequencing Data
Recent advances in single-cell epigenomic techniques have created a growing demand for scATAC-seq analysis. One key analysis task is to determine cell type identity based on the epigenetic data. We introduce scATAnno, a python package designed to automatically annotate scATAC-seq data using large-scale scATAC-seq reference atlases. This workflow generates the reference atlases from publicly available datasets enabling accurate cell type annotation by integrating query data with reference atlases, without the use of scRNA-seq data. To enhance annotation accuracy, we have incorporated KNN-based and weighted distance-based uncertainty scores to effectively detect cell populations within the query data that are distinct from all cell types in the reference data. We compare and benchmark scATAnno against 5 other published approaches for cell annotation, demonstrating superior performance in multiple data sets and metrics. We showcase the utility of scATAnno across multiple datasets, including peripheral blood mononuclear cell (PBMC), triple negative breast cancer (TNBC), and basal cell carcinoma (BCC), and demonstrate that scATAnno accurately annotates cell types across conditions. Overall, scATAnno is a useful tool for scATAC-seq reference building and cell type annotation in scATAC-seq data and can aid in the interpretation of new scATAC-seq datasets in complex biological systems. scATAnno is available online at https://scatanno-main.readthedocs.io/.
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S7. Sequences of Alt-R CRISPR-Cas9 sgRNAs
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S7. Sequences of Alt-R CRISPR-Cas9 sgRNAs
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S11 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S11: Cyclin D1 Kinase Activity is Dispensable for Cyclin D1 to Confer HIF2alpha-Independence in the Cells Lacking All 3 pRB Paralogs
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S11 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S11: Cyclin D1 Kinase Activity is Dispensable for Cyclin D1 to Confer HIF2alpha-Independence in the Cells Lacking All 3 pRB Paralogs
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S3. Sequences of Oligonucleotides Used for the Cloning of CRISPRa and CRISPRko sgRNAs
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S3. Sequences of Oligonucleotides Used for the Cloning of CRISPRa and CRISPRko sgRNAs
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S7: The HIF2 Inhibitor PT2399 Impairs G1/S Traversal by ccRCC Cells
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S7 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S7: The HIF2 Inhibitor PT2399 Impairs G1/S Traversal by ccRCC Cells
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S8: HIF2alpha Inhibitor PT2399 Does Not Induce Apoptosis in ccRCC Cell Lines
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S8 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S8: HIF2alpha Inhibitor PT2399 Does Not Induce Apoptosis in ccRCC Cell Lines
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S2. STR Profile Analysis of TUHR14TKB Cell Line
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Table S2. STR Profile Analysis of TUHR14TKB Cell Line
- Open Access
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Shirole Fig. S6 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S6: Cyclin D1 Kinase Activity is Required for Cyclin D1 to Confer HIF2alpha-Independence
- 3 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessShirole Fig. S6 from Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
Fig. S6: Cyclin D1 Kinase Activity is Required for Cyclin D1 to Confer HIF2alpha-Independence